Global Nanobiotechnology Market Assessment, By Type [0-10 Nm, 10-100 Nm], By Therapeutics [Dental Therapies, Cardiac Therapies, Orthopedic Therapies, Others], By Technology [Nanocrystals, Nanoparticles, Liposomes, Micelles, Nanotubes, Others], By Application [Therapeutics, Nano diagnostics, Tissue Engineering, Gene Therapy, Molecular Nanotechnology, Drug Delivery, Food Safety], By End-user [Pharmaceutical Companies, Research Institutes and Laboratories, Academic Institutions, Others], By Region, Opportunities and Forecast, 2017-2031F
The global nanobiotechnology market is expected to grow due to increased research and development for the rising prevalence of chronic disease and the trend towards nanoscale science.
Home>Industry Reports>Global Nanobiotechnology Market Assessment, Opportunities and Forecast, 2017-2031F
Global nanobiotechnology market size was valued at USD 75.8 billion in 2023, expected to reach USD 143.1 billion in 2031, with a CAGR of 8.27% for the forecast period between 2024 and 2031F. Technological advancements propel the growth of the global nanobiotechnology market, amplify R&D investments, expand uses in healthcare and medicine, and increase the need for personalized medicine and precise drug delivery systems. Moreover, the merging of nanotechnology and biotechnology has sparked advancements in diagnostics, therapeutics, and biomedical research, contributing significantly to market expansion.
The robust expansion of the global nanobiotechnology market relies on various pivotal factors. Foremost, the ongoing progression of technological advancements continually pushes the boundaries of innovation. Nanoscale science and engineering breakthroughs have unlocked unparalleled opportunities, fostering the emergence of fresh tools and methodologies in the domain of nanobiotechnology. Concurrently, heightened investments in research and development (R&D) across diverse sectors have propelled the evolution of nanobiotechnology. These substantial investments drive explorations into novel applications, materials, and methodologies, amplifying the potential for groundbreaking discoveries in healthcare and medicine. The increasing integration of nanotechnology in healthcare and medicine serves as a linchpin for expanding the global nanobiotechnology market.
Nanotechnology's adaptability in these arenas facilitates notable strides in diagnostics, presenting highly sensitive and precise tools for early disease identification. Additionally, in therapeutics, nanobiotechnology transforms drug delivery systems by enabling targeted and controlled medication release, improving treatment effectiveness while minimizing adverse effects. The rising demand for tailored medicine and precise drug delivery systems further propels the growth of global nanobiotechnology market. Nanotechnology's ability to customize treatments and interventions aligns perfectly with the escalating need, fostering the development of therapies personalized to an individual's distinct genetic composition or specific health conditions. Moreover, the convergence of nanotechnology and biotechnology acts as a catalyst, driving breakthroughs in diagnostics, therapeutics, and biomedical research. This fusion fuel innovation, expanding the realm of possibilities in nanobiotechnology and significantly contributing to the expansion and progression of global nanobiotechnology market.
Expanding Uses in Healthcare and Medicine
The increasing incorporation of nanotechnology in healthcare and medicine is a fundamental catalyst for the growing global nanobiotechnology market. Nanotechnology's application in these domains encompasses diverse advancements, particularly in diagnostics, therapeutics, and biomedical research. In diagnostics, nanomaterials facilitate the development of exceptionally sensitive and precise diagnostic instruments, enabling early disease detection with outstanding accuracy. Nanobiotechnology transforms drug delivery systems regarding therapeutics, heightening effectiveness while reducing side effects through targeted and precise release of medicinal compounds. Moreover, nanoscale materials drive the innovation of novel treatments, encompassing nano-formulations for various illnesses, gene therapy, and advancements in regenerative medicine. The fusion of nanotechnology and biotechnology has spurred breakthroughs in biomedical research, fostering sophisticated tools to examine biological systems at a molecular level. These strides facilitate the creation of pioneering medical solutions, propelling the global nanobiotechnology market by promising to reshape healthcare delivery and improve outcomes on a global scale.
Amplified Research and Development Investments
Augmented research and development funding significantly drives the global nanobiotechnology market forward. These increased investments stimulate innovative research, nurturing progress in nanoscale technologies, materials, and approaches. They spark pivotal advancements in healthcare, leading to the development of accurate diagnostic tools, specialized drug delivery systems, and tailored treatments. Through the amplification of R&D funding, the market gains from heightened innovation, expanding the frontiers of nanobiotechnology to provide groundbreaking solutions for healthcare, medicine, and biomedical research worldwide.
For instance, in July 2023, McGill University stated that it had agreements in place to fund two innovative research projects involving lipid nanoparticles (LNPs) with Moderna, Inc., a biotechnology company that is leading the way in messenger RNA (mRNA) therapies and vaccines. Since LNPs are the main means of delivering mRNA strands to the target cells, they play a crucial role in mRNA therapeutics like vaccinations.
Government Initiatives
Governments globally are proactively executing diverse strategies to drive the advancement of the global nanobiotechnology market. These initiatives involve significant financial commitments directed towards research and development, stimulating progress in nanoscale technologies. Furthermore, governments institute favorable policies, frameworks, and partnerships to propel nanobiotechnology forward. They foster collaborations between academia, industry, and research entities, fostering knowledge sharing and hastening market expansion. Additionally, governments allocate resources towards infrastructure and offer incentives, aiming to promote the uptake and commercial viability of nanobiotechnology. The concerted effort supports its broad-ranging implementation across sectors like healthcare, medicine, agriculture, and environmental sustainability.
For instance, the National Nanotechnology Initiative (NNI) in the United States was requested to receive USD 1.99 billion in the President's 2023 Budget in February 2023. Since the NNI's founding in 2001, the total requested, including the 2023 request, has exceeded USD 40.7 billion. The National Nanotechnology Initiative (NNI) is a research and development (R&D) program of the United States government. In addition to supporting a shared infrastructure, enabling resource leveraging without duplication, and establishing shared goals, priorities, and strategies that support agency-specific missions and activities, the NNI improves interagency coordination of nanoscale R&D.
Use of Nanotechnology in Drug Delivery
The rising need for nanotechnology in delivering drugs serves as a key catalyst driving the growth of global nanobiotechnology market. Nanotechnology's role in drug delivery allows for precise, targeted drug application, improving effectiveness while reducing potential side effects. The growing demand arises from nanoscale materials' ability to encapsulate medications, ensure their safe delivery to precise cells or tissues. Additionally, nanotechnology enables controlled release methods, improving therapeutic results. The increasing dependence on nanotechnology in drug delivery underscores its importance, fostering advancements and growth in the nanobiotechnology market, reshaping medication administration for better healthcare outcomes worldwide. To speed up the development of nucleic acid-based medicines and vaccines, Mana.bio, a biotechnology startup that accelerates programmable drug delivery, for instance, announced its AI-based lipid nanoparticle (LNP) delivery platform in October 2023, underwritten by a USD 19.5 million oversubscribed seed rounds. With the funding, Mana.bio may continue developing its unique, specially designed AI LNP platform, which could potentially lead to the creation of novel treatments for a variety of unmet needs by delivering RNA and gene therapies to extrahepatic tissues in the body in a safer and more efficient manner.
Growing Popularity of Nanoparticles
The increasing requirement for nanoparticles acts as a substantial driving factor in advancing the global nanobiotechnology market. These tiny entities hold a central position across diverse fields, notably in healthcare, medicine, and materials science. Their distinct characteristics facilitate precise drug administration, improving treatment effectiveness while reducing adverse effects. Moreover, nanoparticles find utility in diagnostics, imaging, and various industrial domains. The rising interest in these adaptable particles emphasizes their significance in propelling nanobiotechnology, encouraging breakthroughs that transform healthcare methodologies, advanced material development, and a broad range of industrial applications, thereby impacting the market's growth and development. A benchtop instrument for detailed analysis of lipid nanoparticles and other nano-formulations, for example, is scheduled to be launched in September 2023 by SPARTA Biodiscovery, a spin-out company from Imperial College London. According to Jelle Penders, PhD, co-inventor of Single Particle Automated Raman Trapping Analysis (SPARTA), the instrument is the first to simultaneously identify the composition and size of nano-formulations in an automated and label-free manner.
Future Market Scenario
The global nanobiotechnology market's future holds remarkable promise, driven by ongoing innovations and evolving applications. Nanobiotechnology leads the forefront of scientific advancement, offering revolutionary changes across numerous industries. In healthcare, it facilitates precise drug delivery, personalized medicine, and advanced diagnostics, improving treatments with reduced side effects. Its impact spans environmental remediation, agriculture, electronics, and energy sectors, revolutionizing material science and manufacturing processes. Continual research and development efforts, along with increased global investments, drive market expansion. Advancing technology and interdisciplinary collaborations further unlock nanobiotechnology's potential, addressing previously insurmountable challenges. Moreover, the convergence of nanotechnology, biotechnology, and information technology foretells a new era, where nanobiotechnology becomes pivotal in addressing global health, environmental, and societal concerns. The trajectory signifies a promising and transformative path for the global nanobiotechnology market.
Report Scope
“Nanobiotechnology Market Assessment, Opportunities, and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of the global nanobiotechnology market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, COVID-19 impact, opportunities, and forecast between 2024 -2031F. Additionally, the report profiles the leading players in the industry mentioning their respective market share, business model, competitive intelligence, etc.
|
Report Attribute |
Details |
|
Base Year of the Analysis |
2023 |
|
Historical Period |
2017-2022 |
|
Forecast Period |
2024-2031F |
|
Projected Growth Rate |
CAGR of 8.27% between 2024-2031F |
|
Revenue Forecast in 2031 |
USD 143.1 billion |
|
Units |
Revenue in USD billion |
|
Segments Covered |
Type, Therapeutics, Technology, Application, End-user |
|
Regions Covered |
North America, South America, Europe, Asia-Pacific, Middle East and Africa |
|
Moderna, Inc., Generation Bio Co., Sanofi S.A., GlaxoSmithKline Plc, Arrowhead Pharmaceuticals Inc., Bristol-Myers Squibb Company, Merck & Co. Inc., BlueWillow Biologics, Inc., pSivida Corp., Merck KGaA, Starpharma Holdings Ltd. and Thermo Fisher Scientific Inc. |
|
|
Customization Scope |
15% free report customization with purchase |
|
Pricing and Purchase Options |
Avail the customized purchase options to fulfil your precise research needs |
|
Delivery Format |
PDF and Excel through email (subject to the license purchased) |
In this report, global nanobiotechnology market has been segmented into the following categories:
o 10-100 Nm
· By Therapeutics
o Dental Therapies
o Cardiac Therapies
o Orthopedic Therapies
o Others
· By Technology
o Nanocrystals
o Nanoparticles
o Liposomes
o Micelles
o Nanotubes
o Others
· By Application
o Therapeutics
o Nano diagnostics
o Tissue Engineering
o Gene Therapy
o Molecular Nanotechnology
o Drug Delivery
o Food Safety
· By End-user
o Research Institutes and Laboratories
o Academic Institutions
o Others
· By Region
o North America
o South America
o Europe
o Asia-Pacific
o Middle East and Africa
Key Players Landscape and Outlook
Key players in the global nanobiotechnology market proactively participate in collaborative endeavors encompassing strategic alliances, joint research initiatives, and shared investments. Their goal is to collectively leverage resources, expertise, and technological advancements, driving innovation and broadening the horizons of nanobiotechnology applications. These collaborative initiatives allow for the harnessing of complementary strengths, enabling the creation of innovative products and solutions. Furthermore, these partnerships facilitate market exploration across diverse industries and consumer segments, fostering the widespread adoption of nanobiotechnology. It amplifies its influence not only in healthcare, materials science, and environmental sustainability but also in various other domains.
In March 2023, for example, Moderna announced that it had applied for Generation Bio's exclusive stealth cell-targeted lipid nanoparticle (ctLNP) delivery system to find and create non-viral genetic medicines for liver and immune system disorders. This partnership could bring in up to $1.876 billion for Generation Bio. Moderna has obtained the option to license the closed-end DNA (ceDNA) novel build technology from Generation Bio as well as ctLNP.
Key Players Operating in Global Nanobiotechnology Market are:
· Moderna, Inc.
· Generation Bio Co.
· Sanofi S.A.
· GlaxoSmithKline Plc
· Arrowhead Pharmaceuticals Inc.
· Bristol-Myers Squibb Company
· Merck & Co. Inc.
· BlueWillow Biologics, Inc.
· pSivida Corp.
· Merck KGaA
· Starpharma Holdings Ltd.
· Thermo Fisher Scientific Inc.
Markets and Data’s report answers the following questions:
· What is the current and future market size of the product/service in question globally or specific to different countries?
· How are the markets divided into different product/service segments and the market size and growth of each segment?
· What is the market potential of different product segments and their investment case?
· How are the markets predicted to develop in the future and what factors will drive or inhibit growth?
· What is the business environment and regulatory landscape specific to the product/service?
If you can't find what you're searching for or have any custom requirements for global nanobiotechnology market, you may approach our team at info@marketsandata.com.
Table of Contents
1. Research Methodology
2. Project Scope & Definitions
3. Executive Summary
4. Global Nanobiotechnology Market Outlook, 2017-2031F
4.1. Market Size & Forecast
4.1.1.Value
4.1.2.Volume
4.2. By Type
4.2.1.0-10 Nm
4.2.2.10-100 Nm
4.3. By Therapeutics
4.3.1.Dental Therapies
4.3.2.Cardiac Therapies
4.3.3.Orthopedic Therapies
4.3.4.Others
4.4. By Technology
4.4.1.Nanocrystals
4.4.2.Nanoparticles
4.4.3.Liposomes
4.4.4.Micelles
4.4.5.Nanotubes
4.4.6.Others
4.5. By Application
4.5.1.Therapeutics
4.5.2.Nano diagnostics
4.5.3.Tissue Engineering
4.5.4.Gene Therapy
4.5.5.Molecular Nanotechnology
4.5.6.Drug Delivery
4.5.7.Food Safety
4.6. By End-user
4.6.1.Pharmaceutical Companies
4.6.2.Research Institutes and Laboratories
4.6.3.Academic Institutions
4.6.4.Others
4.7. By Region
4.7.1.North America
4.7.2.Europe
4.7.3.South America
4.7.4.Asia-Pacific
4.7.5.Middle East and Africa
4.8. By Company Market Share (%), 2023
5. Global Nanobiotechnology Market Outlook, By Region, 2017-2031F
5.1. North America*
5.1.1.Market Size & Forecast
5.1.1.1. Value
5.1.1.2. Volume
5.1.2.By Type
5.1.2.1. 0-10 Nm
5.1.2.2. 10-100 Nm
5.1.3.By Therapeutics
5.1.3.2. Cardiac Therapies
5.1.3.3. Orthopedic Therapies
5.1.3.4. Others
5.1.4.By Technology
5.1.4.2. Nanoparticles
5.1.4.3. Liposomes
5.1.4.4. Micelles
5.1.4.5. Nanotubes
5.1.4.6. Others
5.1.5.By Application
5.1.5.1. Therapeutics
5.1.5.2. Nano diagnostics
5.1.5.3. Tissue Engineering
5.1.5.4. Gene Therapy
5.1.5.5. Molecular Nanotechnology
5.1.5.6. Drug Delivery
5.1.5.7. Food Safety
5.1.6.By End-user
5.1.6.1. Pharmaceutical Companies
5.1.6.2. Research Institutes and Laboratories
5.1.6.3. Academic Institutions
5.1.6.4. Others
5.1.7.United States*
5.1.7.1. Market Size & Forecast
5.1.7.1.1. Value
5.1.7.1.2. Volume
5.1.7.2. By Type
5.1.7.2.1. 0-10 Nm
5.1.7.2.2. 10-100 Nm
5.1.7.3. By Therapeutics
5.1.7.3.1. Dental Therapies
5.1.7.3.2. Cardiac Therapies
5.1.7.3.3. Orthopedic Therapies
5.1.7.3.4. Others
5.1.7.4. By Technology
5.1.7.4.1. Nanocrystals
5.1.7.4.2. Nanoparticles
5.1.7.4.3. Liposomes
5.1.7.4.4. Micelles
5.1.7.4.5. Nanotubes
5.1.7.4.6. Others
5.1.7.5. By Application
5.1.7.5.1. Therapeutics
5.1.7.5.2. Nano diagnostics
5.1.7.5.3. Tissue Engineering
5.1.7.5.4. Gene Therapy
5.1.7.5.5. Molecular Nanotechnology
5.1.7.5.6. Drug Delivery
5.1.7.5.7. Food Safety
5.1.7.6. By End-user
5.1.7.6.1. Pharmaceutical Companies
5.1.7.6.2. Research Institutes and Laboratories
5.1.7.6.3. Academic Institutions
5.1.7.6.4. Others
5.1.8.Canada
5.1.9.Mexico
*All segments will be provided for all regions and countries covered
5.2. Europe
5.2.1. Germany
5.2.2.France
5.2.3.Italy
5.2.4.United Kingdom
5.2.5.Russia
5.2.6.Netherlands
5.2.7.Spain
5.2.8.Turkey
5.2.9.Poland
5.3. South America
5.3.1.Brazil
5.3.2.Argentina
5.4. Asia-Pacific
5.4.1.India
5.4.2.China
5.4.3.Japan
5.4.4.Australia
5.4.5.Vietnam
5.4.6.South Korea
5.4.7.Indonesia
5.4.8.Philippines
5.5. Middle East & Africa
5.5.1.Saudi Arabia
5.5.2.UAE
5.5.3.South Africa
6. Market Mapping, 2023
6.1. By Type
6.2. By Therapeutics
6.3. By Technology
6.4. By Application
6.5. By End-user
6.6. By Region
7. Macro Environment and Industry Structure
7.1. Supply Demand Analysis
7.2. Import Export Analysis
7.3. Value Chain Analysis
7.4. PESTEL Analysis
7.4.1.Political Factors
7.4.2.Economic System
7.4.3.Social Implications
7.4.4.Technological Advancements
7.4.5.Environmental Impacts
7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5. Porter’s Five Forces Analysis
7.5.1.Supplier Power
7.5.2.Buyer Power
7.5.3.Substitution Threat
7.5.4.Threat from New Entrant
7.5.5.Competitive Rivalry
8. Market Dynamics
8.1. Growth Drivers
8.2. Growth Inhibitors (Challenges and Restraints)
9. Regulatory Framework and Innovation
9.1. Clinical Trials
9.2. Patent Landscape
9.3. Regulatory Approvals
9.4. Innovations/Emerging Technologies
10. Key Players Landscape
10.1. Competition Matrix of Top Five Market Leaders
10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4. SWOT Analysis (For Five Market Players)
10.5. Patent Analysis (If Applicable)
11. Pricing Analysis
12. Case Studies
13. Key Players Outlook
13.1.1. Company Details
13.1.2. Key Management Personnel
13.1.3. Products & Services
13.1.4. Financials (As reported)
13.1.5. Key Market Focus & Geographical Presence
13.1.6. Recent Developments
13.2. Generation Bio Co.
13.3. Sanofi S.A.
13.4. GlaxoSmithKline Plc
13.5. Arrowhead Pharmaceuticals Inc.
13.6. Bristol-Myers Squibb Company
13.7. Merck & Co. Inc.
13.8. BlueWillow Biologics, Inc.
13.9. pSivida Corp.
13.10. Merck KGaA
13.11. Starpharma Holdings Ltd.
13.12. Thermo Fisher Scientific Inc.
*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work
14. Strategic Recommendations
15. About Us & Disclaimer
List of Figures
Figure 1. Global Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 2. Global Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 3. Global Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 4. Global Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 5. Global Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 6. Global Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 7. Global Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 8. Global Nanobiotechnology Market Share (%), By Region, 2017-2031F
Figure 9. North America Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 10. North America Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 11. North America Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 12. North America Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 13. North America Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 14. North America Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 15. North America Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 16. North America Nanobiotechnology Market Share (%), By Country, 2017-2031F
Figure 17. United States Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 18. United States Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 19. United States Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 20. United States Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 21. United States Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 22. United States Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 23. United States Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 24. Canada Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 25. Canada Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 26. Canada Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 27. Canada Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 28. Canada Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 29. Canada Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 30. Canada Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 31. Mexico Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 32. Mexico Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 33. Mexico Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 34. Mexico Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 35. Mexico Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 36. Mexico Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 37. Mexico Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 38. Europe Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 39. Europe Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 40. Europe Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 41. Europe Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 42. Europe Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 43. Europe Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 44. Europe Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 45. Europe Nanobiotechnology Market Share (%), By Country, 2017-2031F
Figure 46. Germany Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 47. Germany Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 48. Germany Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 49. Germany Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 50. Germany Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 51. Germany Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 52. Germany Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 53. France Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 54. France Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 55. France Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 56. France Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 57. France Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 58. France Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 59. France Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 60. Italy Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 61. Italy Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 62. Italy Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 63. Italy Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 64. Italy Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 65. Italy Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 66. Italy Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 67. United Kingdom Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 68. United Kingdom Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 69. United Kingdom Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 70. United Kingdom Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 71. United Kingdom Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 72. United Kingdom Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 73. United Kingdom Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 74. Russia Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 75. Russia Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 76. Russia Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 77. Russia Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 78. Russia Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 79. Russia Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 80. Russia Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 81. Netherlands Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 82. Netherlands Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 83. Netherlands Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 84. Netherlands Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 85. Netherlands Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 86. Netherlands Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 87. Netherlands Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 88. Spain Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 89. Spain Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 90. Spain Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 91. Spain Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 92. Spain Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 93. Spain Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 94. Spain Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 95. Turkey Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 96. Turkey Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 97. Turkey Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 98. Turkey Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 99. Turkey Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 100. Turkey Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 101. Turkey Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 102. Poland Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 103. Poland Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 104. Poland Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 105. Poland Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 106. Poland Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 107. Poland Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 108. Poland Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 109. South America Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 110. South America Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 111. South America Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 112. South America Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 113. South America Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 114. South America Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 115. South America Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 116. South America Nanobiotechnology Market Share (%), By Country, 2017-2031F
Figure 117. Brazil Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 118. Brazil Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 119. Brazil Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 120. Brazil Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 121. Brazil Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 122. Brazil Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 123. Brazil Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 124. Argentina Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 125. Argentina Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 126. Argentina Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 127. Argentina Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 128. Argentina Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 129. Argentina Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 130. Argentina Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 131. Asia-Pacific Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 132. Asia-Pacific Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 133. Asia-Pacific Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 134. Asia-Pacific Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 135. Asia-Pacific Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 136. Asia-Pacific Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 137. Asia- Pacific Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 138. Asia-Pacific Nanobiotechnology Market Share (%), By Country, 2017-2031F
Figure 139. India Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 140. India Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 141. India Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 142. India Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 143. India Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 144. India Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 145. India Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 146. China Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 147. China Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 148. China Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 149. China Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 150. China Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 151. China Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 152. China Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 153. Japan Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 154. Japan Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 155. Japan Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 156. Japan Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 157. Japan Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 158. Japan Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 159. Japan Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 160. Australia Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 161. Australia Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 162. Australia Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 163. Australia Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 164. Australia Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 165. Australia Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 166. Australia Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 167. Vietnam Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 168. Vietnam Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 169. Vietnam Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 170. Vietnam Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 171. Vietnam Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 172. Vietnam Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 173. Vietnam Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 174. South Korea Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 175. South Korea Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 176. South Korea Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 177. South Korea Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 178. South Korea Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 179. South Korea Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 180. South Korea Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 181. Indonesia Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 182. Indonesia Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 183. Indonesia Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 184. Indonesia Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 185. Indonesia Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 186. Indonesia Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 187. Indonesia Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 188. Philippines Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 189. Philippines Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 190. Philippines Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 191. Philippines Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 192. Philippines Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 193. Philippines Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 194. Philippines Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 195. Middle East & Africa Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 196. Middle East & Africa Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 197. Middle East & Africa Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 198. Middle East & Africa Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 199. Middle East & Africa Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 200. Middle East & Africa Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 201. Middle East & Africa Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 202. Middle East & Africa Nanobiotechnology Market Share (%), By Country, 2017-2031F
Figure 203. Saudi Arabia Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 204. Saudi Arabia Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 205. Saudi Arabia Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 206. Saudi Arabia Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 207. Saudi Arabia Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 208. Saudi Arabia Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 209. Saudi Arabia Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 210. UAE Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 211. UAE Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 212. UAE Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 213. UAE Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 214. UAE Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 215. UAE Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 216. UAE Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 217. South Africa Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 218. South Africa Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 219. South Africa Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 220. South Africa Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 221. South Africa Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 222. South Africa Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 223. South Africa Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 224. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 225. By Therapeutics Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 226. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 227. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 228. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 229. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023
List of Tables
Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects
Frequently Asked Questions
What are the regions covered in the final report for global nanobiotechnology market?
Who are the key players operating in the global nanobiotechnology market?
What are the major factors influencing the growth of global nanobiotechnology market?
What is the market size and growth rate of global nanobiotechnology market?
See Related Reports
Global Coffee Market Assessment, Opportunities and Forecast, 2017-2031F
Global coffee market is expected to experience growth due to consumers’ increasing preference for organic and premium coffee that offers freshness, superior quality of beans and roasts, and unique flavor profile. Additionally, the product innovation,....Read More
Published on
July 2024
4,500
Global Home Theater System Market Assessment, Opportunities and Forecast, 2017-2031F
Global home theater system market is expected to experience growth due to technological advancements, increasing disposable incomes, rising demand for high-definition content, integration with smart home systems, and the surge in streaming services p....Read More
Published on
July 2024
4,500
Global Baby Food Market Assessment, Opportunities and Forecast, 2017-2031F
Global baby food market is expected to experience growth due to factors such as consumers’ increasing awareness of the nutrients which are essential for babies development and introduction of wide variety of baby foods in the market from milk powders....Read More
Published on
July 2024
4,500
Global Isoflavones Market Assessment, Opportunities and Forecast, 2017-2031F
Global isoflavones market is expected to experience growth due to increasing consumer health awareness, rising demand for functional foods and nutraceuticals, advancements in extraction technologies, and expanding applications in cosmetics, pharmaceu....Read More
Published on
July 2024
4,500
Purchase Options
USD ($)
i
3,000
i
4,500
i
5,700
i
8,200
Tired of Searching?
Looking for Customization?
Some other doubt?
Need insights from a cohort?
REACH US
